Inhalation Sciences
A novel lab instrument that changes the way we understand how particles and pharmaceuticals affect the human body, contributing to a better treatment of asthma, diabetes and infections.
Launch date
Employees
Market cap
€7.2m
Enterprise valuation
€6m (Public information from Sep 2024)
Share price
SEK4.34
Company register number 556665-6038
Huddinge kommun Stockholm County (HQ)
Financials
Estimates*
| EUR | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | 1.0m | <1m | 1.1m | 1.9m | 4.2m | 7.2m |
| % growth | 61 % | 18 % | (2 %) | 11 % | 76 % | 119 % | 72 % |
| EBITDA | (<1m) | (<1m) | (1.7m) | (<1m) | (<1m) | 1.3m | 1.5m |
| % EBITDA margin | (82 %) | (75 %) | (167 %) | (89 %) | (15 %) | 30 % | 20 % |
| Profit | (<1m) | 1.1m | (1.9m) | (1.3m) | (<1m) | 1.1m | <1m |
| % profit margin | (49 %) | 109 % | (189 %) | (120 %) | (27 %) | 26 % | 14 % |
| EV / revenue | 7.7x | 10.9x | 11.5x | 5.5x | 3.1x | 1.4x | 1.0x |
| EV / EBITDA | -9.4x | -14.6x | -6.9x | -6.2x | -20.7x | 4.8x | 5.0x |
| R&D budget | <1m | <1m | <1m | <1m | - | - | - |
| R&D % of revenue | 64 % | 67 % | 98 % | 73 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | SEK5.9m | Early VC | |
| N/A | SEK3.5m | Early VC | |
| N/A | N/A | IPO | |
* | N/A | €125k | Grant |
| Total Funding | €1.2m | ||
Recent News about Inhalation Sciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.